子宫内膜透明细胞癌的中国专家共识(2020 年版)

2020-08-30 妇产科相关专家组(统称) 医学综述.2020,26(16):3121-3129.

子宫内膜透明细胞癌( UCCC) 是一种临床罕见、侵袭性极强的子宫内膜癌。鉴于疾病的罕见性,临床研究中很难实施针对UCCC 的大型前瞻性研究,致使UCCC 的诊断、治疗面临诸多挑战,目前相关的研究数据

中文标题:

子宫内膜透明细胞癌的中国专家共识(2020 年版)

发布日期:

2020-08-30

简要介绍:

子宫内膜透明细胞癌( UCCC) 是一种临床罕见、侵袭性极强的子宫内膜癌。鉴于疾病的罕见性,临床研究中很难实施针对UCCC 的大型前瞻性研究,致使UCCC 的诊断、治疗面临诸多挑战,目前相关的研究数据多来自小型的回顾性研究或其他大型研究中的亚组分析。近年来,随着UCCC 治疗的相关研究数据逐渐更新,本共识对UCCC 临床病理学特点、术前辅助检查的选择、初始治疗及复发后治疗等逐一规范,以供临床参考。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=子宫内膜透明细胞癌的中国专家共识_2020年版_王建六.pdf)] GetToolGuiderByIdResponse(projectId=1, id=0ad731c00198097e, title=子宫内膜透明细胞癌的中国专家共识(2020 年版) , enTitle=, guiderFrom=医学综述.2020,26(16):3121-3129., authorId=0, author=, summary=子宫内膜透明细胞癌( UCCC) 是一种临床罕见、侵袭性极强的子宫内膜癌。鉴于疾病的罕见性,临床研究中很难实施针对UCCC 的大型前瞻性研究,致使UCCC 的诊断、治疗面临诸多挑战,目前相关的研究数据, cover=https://img.medsci.cn/2020929/1601394226278_2020535.jpg, journalId=0, articlesId=null, associationId=922, associationName=妇产科相关专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Sun Aug 30 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>子宫内膜透明细胞癌( UCCC) 是一种临床罕见、侵袭性极强的子宫内膜癌。鉴于疾病的罕见性,临床研究中很难实施针对UCCC 的大型前瞻性研究,致使UCCC 的诊断、治疗面临诸多挑战,目前相关的研究数据多来自小型的回顾性研究或其他大型研究中的亚组分析。近年来,随着UCCC 治疗的相关研究数据逐渐更新,本共识对UCCC 临床病理学特点、术前辅助检查的选择、初始治疗及复发后治疗等逐一规范,以供临床参考。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=106928, tagName=子宫内膜透明细胞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=850, guiderKeyword=子宫内膜癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4574, appHits=234, showAppHits=0, pcHits=903, showPcHits=4340, likes=2, shares=9, comments=13, approvalStatus=1, publishedTime=Wed Sep 30 00:26:26 CST 2020, publishedTimeString=2020-08-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Sep 29 23:43:52 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:37:01 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=子宫内膜透明细胞癌的中国专家共识_2020年版_王建六.pdf)])
子宫内膜透明细胞癌的中国专家共识_2020年版_王建六.pdf
下载请点击:
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1193716, encodeId=25871193e1604, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b292271319, createdName=121a6444m87暂无昵称, createdTime=Tue Feb 15 19:49:20 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185617, encodeId=9f48118561e3b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Tue Jan 18 13:59:37 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072806, encodeId=0e5910e280611, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34b65726584, createdName=ms9000002039039583, createdTime=Mon Nov 22 11:37:09 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007710, encodeId=3fda100e710b3, content=继续暂积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/4c4de76e31fd40d2b82a879e214a2327/5bba23ac46714ffa9debd32500090845.jpg, createdBy=34d85449855, createdName=ms8000000769309498, createdTime=Fri Aug 13 20:22:21 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970107, encodeId=833d9e01073e, content=认真学习领会, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/e740842d354c489fbbdac97073052a4b/cf8f87b3832d42b0b4614673e105b450.jpg, createdBy=7ee15510944, createdName=郭锐, createdTime=Tue Jun 01 17:15:44 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2022-02-15 121a6444m87暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1193716, encodeId=25871193e1604, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b292271319, createdName=121a6444m87暂无昵称, createdTime=Tue Feb 15 19:49:20 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185617, encodeId=9f48118561e3b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Tue Jan 18 13:59:37 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072806, encodeId=0e5910e280611, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34b65726584, createdName=ms9000002039039583, createdTime=Mon Nov 22 11:37:09 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007710, encodeId=3fda100e710b3, content=继续暂积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/4c4de76e31fd40d2b82a879e214a2327/5bba23ac46714ffa9debd32500090845.jpg, createdBy=34d85449855, createdName=ms8000000769309498, createdTime=Fri Aug 13 20:22:21 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970107, encodeId=833d9e01073e, content=认真学习领会, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/e740842d354c489fbbdac97073052a4b/cf8f87b3832d42b0b4614673e105b450.jpg, createdBy=7ee15510944, createdName=郭锐, createdTime=Tue Jun 01 17:15:44 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2022-01-18 niu拾柒

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1193716, encodeId=25871193e1604, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b292271319, createdName=121a6444m87暂无昵称, createdTime=Tue Feb 15 19:49:20 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185617, encodeId=9f48118561e3b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Tue Jan 18 13:59:37 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072806, encodeId=0e5910e280611, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34b65726584, createdName=ms9000002039039583, createdTime=Mon Nov 22 11:37:09 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007710, encodeId=3fda100e710b3, content=继续暂积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/4c4de76e31fd40d2b82a879e214a2327/5bba23ac46714ffa9debd32500090845.jpg, createdBy=34d85449855, createdName=ms8000000769309498, createdTime=Fri Aug 13 20:22:21 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970107, encodeId=833d9e01073e, content=认真学习领会, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/e740842d354c489fbbdac97073052a4b/cf8f87b3832d42b0b4614673e105b450.jpg, createdBy=7ee15510944, createdName=郭锐, createdTime=Tue Jun 01 17:15:44 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-11-22 ms9000002039039583

    很实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1193716, encodeId=25871193e1604, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b292271319, createdName=121a6444m87暂无昵称, createdTime=Tue Feb 15 19:49:20 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185617, encodeId=9f48118561e3b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Tue Jan 18 13:59:37 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072806, encodeId=0e5910e280611, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34b65726584, createdName=ms9000002039039583, createdTime=Mon Nov 22 11:37:09 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007710, encodeId=3fda100e710b3, content=继续暂积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/4c4de76e31fd40d2b82a879e214a2327/5bba23ac46714ffa9debd32500090845.jpg, createdBy=34d85449855, createdName=ms8000000769309498, createdTime=Fri Aug 13 20:22:21 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970107, encodeId=833d9e01073e, content=认真学习领会, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/e740842d354c489fbbdac97073052a4b/cf8f87b3832d42b0b4614673e105b450.jpg, createdBy=7ee15510944, createdName=郭锐, createdTime=Tue Jun 01 17:15:44 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-08-13 ms8000000769309498

    继续暂积分

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1193716, encodeId=25871193e1604, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b292271319, createdName=121a6444m87暂无昵称, createdTime=Tue Feb 15 19:49:20 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185617, encodeId=9f48118561e3b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Tue Jan 18 13:59:37 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072806, encodeId=0e5910e280611, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34b65726584, createdName=ms9000002039039583, createdTime=Mon Nov 22 11:37:09 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007710, encodeId=3fda100e710b3, content=继续暂积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/4c4de76e31fd40d2b82a879e214a2327/5bba23ac46714ffa9debd32500090845.jpg, createdBy=34d85449855, createdName=ms8000000769309498, createdTime=Fri Aug 13 20:22:21 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970107, encodeId=833d9e01073e, content=认真学习领会, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/e740842d354c489fbbdac97073052a4b/cf8f87b3832d42b0b4614673e105b450.jpg, createdBy=7ee15510944, createdName=郭锐, createdTime=Tue Jun 01 17:15:44 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-06-01 郭锐

    认真学习领会

    0

拓展阅读

2015 ASCO/ASRO:子宫内膜癌术后放射治疗循证指南

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2016-05-30

2015 ESMO/ESGO/ESTRO共识会议:子宫内膜癌的诊断、治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2015-12-02

2015 ACOG/SGO临床指南(NO.149):子宫内膜癌

美国妇产科医师学会(ACOG,American College of Obstetricians and Gynecologists) · 2015-04-01

子宫内膜癌筛查和早期诊断专家共识(草案)

中国肿瘤科相关专家小组(统称) · 2017-10-30

2018 ESUR指南:子宫内膜癌MRI分期(更新)

欧洲泌尿生殖放射学会(ESUR,European Society of Urogenital Radiology) · 2018-07-11